purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation bcrx earnings call period ending december image source motley fool biocryst pharmaceutical bcrx q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorgood day welcome biocryst fourthquarter earnings conference call operator instruction please note event recorded would like turn conference john bluth biocryst please go aheadjohn bluth senior vice president investor relation corporate communication thank much good morning welcome biocrysts fourthquarter yearend corporate update financial result conference call today press release accompanying slide available website participating today ceo jon stonehouse cfo anthony doyle chief commercial officer charlie gayer chief medical officer dr ryan arnold following remark answer question begin please note today conference call contain forwardlooking statement including statement regarding future result unaudited forwardlooking financial information well company future performance andor achievement statement subject known unknown risk uncertainty may cause actual result performance achievement materially different future result performance expressed implied presentationyou place undue reliance forwardlooking statement additional information including detailed discussion risk factor please refer company document filed security exchange commission accessed website addition today conference call includes nongaap pro forma financial measure reconciliation nongaap measure directly comparable gaap financial measure please refer earnings press release posted press release section investor relation website biocrystcom would like turn call jon stonehouse jon stonehouse chief executive officer thanks john another impressive year orladeyo starting generating million revenue third year launch continue make great progress toward goal global peak revenue billion let explain late last year laid set assumption would lead u million peak sale yous first assumption exit last year base approximately patient therapy actually exited year base patient therapy second added net new patient well average per year need third improved percentage paid therapy commercially insured part business inaudible fourth made modest net annual price increase yous four assumption charlies audio gap executed met exceeded goal great execution real progress toward goal today focus prepared remark orladeyo financials start ryan cover data presented quad ai past weekend many patient orladeyo seeing excellent control hae along convenience one daily dosing pas ryanryan arnold chief medical officer thanks jon privilege career work several therapy helped change life patient live chronic lifealtering disease important lesson learned longterm data particularly evidence real world experience especially rare disease critical understanding treatment address unmet need change life differing patient population exciting time orladeyo three full year market seeing consistent picture emerge building evidence realworld experience longterm clinical data telling consistent story orladeyo provide meaningful benefit variety hae patient recently published final analysis data open label longterm extension portion apex study berotralstat patient started blinded berotralstat milligram completed full two year study average reduction hae attack compared baseline rate measure attack percentage meaningful people living hae get chance live normal life minimizing attack burden experience meaningful improvement everyday quality life avoiding unnecessary potential burden treatment orladeyotreated patient longterm study reported rapid sustained improvement baseline attack per month attack per month two year median attack rate zero month patient also reported meaningful longterm improvement quality life treatment satisfaction overall safety profile reassuring people living lifelong disease kind change sustained low rate attack one pill day transformative many patient longterm data clinical program tell important part story consistently reinforced expanding base realworld evidence past weekend quad ai meeting washington dc presented five poster showing strong real world evidence orladeyo variety patient hae patient experiencing real world consistent twoyear clinical data patient type ii hae reporting longterm median attack rate around half attack per month switching prophylactic therapy account patient fewer attack orladeyo prior therapy patient report rapid sustained reduction attack maintaining attackfree status regardless whether baseline monthly attack rate high low prior starting orladeyo data effect regardless baseline attack rate consistent evidence presented clinical trial patient diagnosed physician hae normal cinhibitor level also reporting rapid sustained reduction attack orladeyo seeing similar outside united state particularly country like france patient followed comprehensive program active involvement healthcare provider real world evidence demonstrating long term safety effectiveness orladeyo exciting team hearing story orladeyo past three year data illustrate favorable treatment option people living hae even exciting data presented quad ai start continue generate realworld evidence orladeyo coming year look forward showing treatment help change life patient family impacted hae turn charlie describe emerging evidence translating commercial effortscharlie gayer chief commercial officer thanks ryan jon noted earlier recently described consistent net patient growth per year next several year put u track million sale united state entering fourth year market much track added orladeyo patient yous realworld evidence ryan described help explain growth patient would like convenience doubt demand efficacy control attack real world data orladeyo clearly demonstrates patient efficacy convenience tradeoff team done good job launching orladeyo end patient experience dictate far go ryan shared switching orladeyo prophylaxis therapy patient experienced median rate half attack per month mean patient many month attackfree attack need treated often le severe half attack per month also important benchmark market research large sample hae patient reported previously medical congress half attack per month match level attack control reported patient taking injectable prophylaxis therapy real world low consistent rate attack orladeyo meet patient expectation know experience perfect control unlikely product many patient able get level control oral oncedaily therapy transforming live hae recently conducted anonymous market research project sizable cohort patient experience orladeyo asked part exercise write letter orladeyo describing experience theme gave confidence changed life feel like normal person common strong evidence patient also continues shape prescriber expectation give confidence large quarterly survey allergist showed consistently expected grow proportion hae patient treated orladeyo next month noted press release today number patient paid therapy longterm free product program also grew tracking physician prediction currently patient orladeyo switched prophylaxes allergist survey expect twothirds orladeyo growth next year come switch injectable prophylaxis end orladeyo prescribed time united state mean least diagnosed treated patient yet tried orladeyo yous healthcare provider prescribed orladeyo including new prescribers clearly opportunity hae treater many patient market research predicts way opportunity front u behind u growing body evidence orladeyo changing patient life going help u get pas anthony describe financial performanceanthony doyle chief financial officer thanks charlie great see strong q full year orladeyo revenue performance continued underlying strength net new patient add giving u confidence achieving million million global orladeyo revenue year path peak sale billion find detailed fourthquarter financials today earnings press release call attention item total revenue quarter came million million came orladeyo orladeyos net sale full year million increase million year year million global orladeyo revenue million came yous sale remaining million coming exyous fullyear basis yous orladeyo sale contributed million million global total remaining million coming exyous operating expense including noncash stock comp quarter approximately million included significant onetime expense include million attributable rd reorganization including cost related reduction force postponement expansion discovery center birmingham alabama million upfront payment made clearside related partnership well around million cmc trial cost related partnership decision bcx explain increase opex q operating expense including noncash stock comp full year came million excluding million restructuring onetime adjustment mentioned landed within guidance range expect quarterly expense normalize low mid million range taking u line fullyear guidance million million essentially flat cash end year million net cash utilization quarter million january provided guidance nearterm timeline achieve profitability expect revenue exceed opex including noncash stock comp result u generating operating profit year additionally revenue exceeding million put u tier whereby incremental revenue profitable blended royalty rate reduced secondhalf expect approaching net income cash flow positivity quarterly basis expect achieve net income cash flow positivity fullyear basis achieving independence capital market also continue invest expanding global reach orladeyo expanding label pediatric indication also advancing exciting early stage pipeline put company strong position moving forward operator open qa question answer operatorwe begin questionandanswer session operator instruction time pause momentarily assemble roster first question come tazeen ahmad bank america please go aheadtazeen ahmad bank america merrill lynch analyst hi guy good morning thanks taking question give u little bit color regarding patient able add last year came said higher anticipated particular profile patient added expecting general sense level baseline attack patient switching particular drug another drug followup thanksjon stonehouse chief executive officer sure tazeen really profile expecting since beginning launch getting patient different profile ryan laid data excuse sorry data presented weekend quad ai regardless baseline attack rate regardless background therapy patient really well orladeyojohn bluth senior vice president investor relation corporate communication want take rest ryanryan arnold chief medical officer phenotype think asking baseline attack rate phenotype seeing particular group going switching orladeyojon stonehouse chief executive officer yes call attention slide slide deck speak background baseline attack rate see despite varying attack rate high low patient well orladeyo slide specifically call baseline attack rate baseline hae type type ii patient well achieving attack rate day rapid sustained reduction attack rate basically variety patient benefit orladeyo regardless baseline attack rate ischarlie gayer chief commercial officer yes tazeen really predict goal get everybody try see work themtazeen ahmad bank america merrill lynch analyst want ask whether real life seeing something different relative seen clinical trial seems like answer maybe followup thinking discontinuation rate goforward basis trending change time launched thanksjon stonehouse chief executive officer charlie alivecharlie gayer chief commercial officer inaudible asthma attack discontinuation really steady last year still patient start orladeyo get patient month discontinuation think relating earlier question see retention rate regardless patient background regardless attack rate regardless whether switching prophylaxis coming acute staying rate yeartazeen ahmad bank america merrill lynch analyst ok thank youoperatorthe next question come brian abraham rbc capital market please go aheadbrian abraham rbc capital market analyst hey good morning guy thanks taking question congrats continued progress curious could talk little bit guess sale marketing strategy year relative last year expect guess continued pullthrough team territory change implemented expect focus additional sga investment year change commercial approach strategy expected greater proportion opportunity coming switcher versus patient ondemand onlyjon stonehouse chief executive officer charlie want take thatcharlie gayer chief commercial officer yes hey brian one reason think well last year make adjustment team beginning end last year additional sale folk additional patient service market access added everyone active really comfortable role working well together think big part performance going forward question change kind data ryan presented think really critical inaudible getting patient physician comfortable switching injectable prophylaxis orladeyo opportunity patient really benefit think seeing customer starting understand focus messagingjon stonehouse chief executive officer brian would add brian abraham rbc capital market analyst got thank youjon stonehouse chief executive officer one thing would add brian charlie mentioned increasing comp one thing seeing quad ai another place standingroomonly session quad ai confidence doc really high compare year ago people still kind fence really experience seeing work extremely well patient effect really positive orladeyo patientsbrian abraham rbc capital market analyst got thanks jon maybe quick followup sound like got visibility getting goal paid rate end decade think get paid rate year relative embedded guidance much potential upside could versus guidance thing go better expected front hop back queue thankscharlie gayer chief commercial officer brian said number yes confident get going take u year announced morning press release ended last year rate make incremental improvement expect major change going jump straight get probably time framebrian abraham rbc capital market analyst got thanks charlie thanks againoperatorthe next question come jessica fye jpmorgan please go aheadjessica fye jpmorgan chase company analyst hey guy good morning thanks taking question talk extent near longterm topline expectation orladeyo reflects introduction le frequently dosed injectables oral thank youcharlie gayer chief commercial officer hi jess take account introduction new product including new injectables possibly future new oral jinky rosselli described last earnings call patient therapy well tend really sticky therapy patient well orladeyo see moving therapy key part differentiated product oncedaily oral something patient healthcare provider really want new injectable therapy offer incremental benefit highly differentiated way orladeyo isjon stonehouse chief executive officer jess flip question around ask would go another product incremental benefit think charlie presented today ryan presented patient sacrificing efficacy convenience drug work spectacularly well certain patient onceaday drug incremental benefit going cause switch seen getting switch incremental benefit question efficacy right controlled drug betterjessica fye jpmorgan chase company analyst thank youjon stonehouse chief executive officer welcomeoperatorthe next question come liisa bayko evercore isi please go aheadliisa bayko evercore isi analyst hi follow mean half attack rate per month right one every two month six per year switching prophylaxis would like type patient would interested maybe trying something else would like one question actually question beyond thatjon stonehouse chief executive officer ryan want tackle one mean bottom line nobody better kind standard every drug breakthrough attack number mixture people attack ryan know anything else addryan arnold chief medical officer yes jon alluded mean seeing similar attack control injectable therapy view tradeoff trade patient want attack control want added convenience quality life improvement reported clinical study well realworld evidence half attack per month well include attack severity shared manageable notable improvement look similar injectables term attack rate controljon stonehouse chief executive officer yes liisa get confused number attackrate reduction pivotal study confidence interval study overlap work bottom line perfect breakthrough attacksliisa bayko evercore isi analyst ok done convenience analysis like market research sort like longacting agent seems like point might tip balance taking oral pill frequent injection realize people like injection guess like elasticity wayjon stonehouse chief executive officer yes really good question super paranoid one thing asked jinky tipping point frequency injectable dosing would make attractive oncedaily oral found yet mean run research found yet liisa bayko evercore isi analyst okjon stonehouse chief executive officer keep lookingryan arnold chief medical officer sorry interrupt would add think people underestimate fear injection patient experience convenient think fear fatigue injection underestimated hear continuously physician patient well seeking convenience well aspect normal normal life carrying around onceaday oral feel normal lot patientsliisa bayko evercore isi analyst ok great quick question kind go math like many patient treated far many patient like hae patient many need try orladeyo given kind like stickiness product like maybe whatever half patient end like sticking long term kind like go get sort million numberjon stonehouse chief executive officer start work backwardscharlie gayer chief commercial officer yes liisa near end remark today pointed least patient yet tried orladeyo based previous estimate diagnosed treated patient prescription date least another patient hearing physician patient expect lot trial plenty room growliisa bayko evercore isi analyst ok like think need get number like half need try amountcharlie gayer chief commercial officer probably pretty good estimate need get patient sticky peak halfway pointliisa bayko evercore isi analyst great thank much guysjon stonehouse chief executive officer welcomeoperatorthe next question come stacy ku td cowen please go aheadstacy ku td cowen analyst thanks taking question first question around kind potential implication change medicare part redesign due iri could potential impact patient volume decrease max outofpocket spend would timing something like one followup question asked characterize commentary around clinician prescribing academic community really still split thanks muchcharlie gayer chief commercial officer thanks stacy ira particularly next year max outofpocket shift think advantage patient term affordability important next year paid course year month increment think increase affordability likely increase rate orladeyo think really change volume patient treated going affect rate far clinician see great mix see academic physician well lot community physician said healthcare provider prescribed far really distributed evenly across decile healthcare provider potential index consistent way every quarter getting academic communitystacy ku td cowen analyst understood followup mean think rate improves kind ira change think able kind switch patient paid drug fair way think itcharlie gayer chief commercial officer yes yes next year beyondstacy ku td cowen analyst ok wonderful thank youjon stonehouse chief executive officer thanksoperatorthe next question come serge belanger needham co please go aheadserge belanger needham company analyst hi good morning thanks taking question guess first one charlie give little color q seasonality year similar prior year second question guess jon maybe rest team think consistent expect competition oral prophylactic end decade curious thought oral ondemand treatment impact could market thankscharlie gayer chief commercial officer sure hey serge start q yes expect similar seasonality first quarter revenue versus q really strong q actually think percentage reduction could little bit year think drop q probably mids revenue qjon stonehouse chief executive officer regard oral competition specifically ondemand therapy mean certainly argue oral important oral alternative breakthrough attack think great choice patient think another benefit alloral option would fantastic right prophy breakthrough attack take oral demandserge belanger needham company analyst great thanksjon stonehouse chief executive officer welcomeoperatoroperator instruction next question come gena wang barclays please go aheadgena wang barclays analyst thank taking question one regarding data report think look slide look number patient twothird patient mean beginning patient number end patient number onethird patient continue end data report color could give regarding twothird patientsjon stonehouse chief executive officer yes well maybe let start ryanryan arnold chief medical officer yes mean thanks question patient reporting selfreporting attack rate realworld data always limitation term recorded month patient may share attack rate mean necessarily come therapy patient seen slide completed day therapy still waiting complete time frame include analysisjon stonehouse chief executive officer yeah keep somebody study two year challenging certainly remember patient well drug got retention uncommon see people succeed see resultscharlie gayer chief commercial officer underline ryan said make sure really clear realworld evidence measure patient based length time therapy opportunity reach day started later time point dynamic sample course patient drop represents well patient well orladeyo really well sticking therapyjon stonehouse chief executive officer point gena patient well really well druggena wang barclays analyst ok great thank youoperatorthe next question come francois brisebois oppenheimer please go aheadfrancois brisebois oppenheimer company analyst hi thanks taking question wondering term discontinuation rate lead discontinuation rate patient well reason discontinue usually end doingcharlie gayer chief commercial officer thanks francois discontinuation rate two main reason discontinuation surprising number one reason perceived lack efficacy said drug perfect one hae therapy everybody number one reason reported number two reason adverse event specifically gastrointestinal surprising given product label clinical trial experience know patient give early part messaging physician others set expectation breakthrough attack might gi event gi event tend go away week therapy patient important patient give early actually see patient starting orladeyo actually restarts people gave past came back knew given earlyjon stonehouse chief executive officer francois john send slide one slide previous deck show pattern discontinuation two year flat think pretty good idea pattern got year got youfrancois brisebois oppenheimer company analyst understood help understand little bit yous versus exyous dynamic term growth assumption expectation challenge maybe exyous happening yous color would helpful thank youcharlie gayer chief commercial officer sure exyous first biggest challenge biggest time factor getting market access exyous market always take longer country rolling time number country europe example like germany youk france got market access year ago getting market access others like spain italy one factor pricing lot lower exyous take four five exyous patient add one yous patient strategy much volume strategy outside yous finally seeing real world country market access launched consistent pattern patient add depending market hae market dynamic sometimes patient switching prophylaxis sometimes growing prophylaxis market drug like orladeyo peak expect exyous equal million billion sale see far give u confidence get therejon stonehouse chief executive officer takhzyro analog right time yous start flatten exyous continues grow overall growth brand still expecting right nowfrancois brisebois oppenheimer company analyst understood thank muchjon stonehouse chief executive officer welcomeoperatorthe next question come maury raycroft jefferies please go aheadmaury raycroft jefferies analyst hi good morning thanks taking question wanted ask clarifying question seasonality quarter reason first quarter budget issue external charity increase number patient free drug program seeing year farcharlie gayer sure maury one situation medicare issue got little bit insight would say solved yet seem worse solved think next year said earlier ira rolling fully expectation budget issue solved main reason dip q broader percentage patient getting reauthorizations happens drop many patient back temporarily free product also first quarter highest hit gross net commercial market helping pick patient copays majority happens first quarterjon stonehouse chief executive officer see corresponding nice pop second quarter get people back paidmaury raycroft jefferies analyst got make sense one quick question proportion new patient shortterm quick start long average take convert patient longterm pay patientscharlie gayer net growth across whole year say ended year sorry patient either paid therapy longterm free product also sizable chunk patient shortterm quick start new patient coming usually take u get product quickly patient get either paid free product within monthmaury raycroft jefferies analyst got ok thanks taking questionsjon stonehouse chief executive officer welcomeoperatoryour final question today come john inaudible citizen please go aheadunknown speaker hi catherine john question thinking profitability versus earlier pipeline kind prioritizing question data coming still coming midyear pnh trial thanksanthony doyle chief financial officer yeah think clear past profitability excited get point independent capital market seeing past year convergence line revenue opex continue see year beyond able generate operating profit year getting toward cash positivity eps end next year achieving think put u right spot time continuing invest early phase pipeline two thing coexist actually opportunity able invest whatever move fast period early phase pipeline generated announced november fact early phase put u spot expenditure within next kind three year meaningful would get pivotal trial think company great spot anything accelerate absolutely willjon stonehouse chief executive officer nothing update nothing changed timelineunknown speaker thank youjon stonehouse chief executive officer welcomeoperatorthis concludes questionandanswer session would like turn conference back jon stonehouse closing remarksjon stonehouse chief executive officer thank one thing hearing investor many thing coming hard keep opportunity invest camp question may want stop ask many company portfolio growing product discovery engine created growing product pipeline came discovery engine going create another growing product accelerated path profitability probably going cash flow positive near second half next year answer none want diversify pipe portfolio reach u happy get speed company answer question may great day thanks interest biocrystoperatoroperator signoff duration minutescall participantsjohn bluth senior vice president investor relation corporate communicationsjon stonehouse chief executive officerryan arnold chief medical officercharlie gayer chief commercial officeranthony doyle chief financial officertazeen ahmad bank america merrill lynch analystbrian abraham rbc capital market analystjessica fye jpmorgan chase company analystliisa bayko evercore isi analyststacy ku td cowen analystserge belanger needham company analystgena wang barclays analystfrancois brisebois oppenheimer company analystmaury raycroft jefferies analystcharles gayerunknown speaker bcrx analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy